Tissue concentration of systemically administered antineoplastic agents in human brain tumors

Journal of Neuro-Oncology

Volumn 104, Issue 3, 2011, Pages 629-638

  Pitz, Marshall W ^a   Desai, Arati ^b   Grossman, Stuart A ^c   Blakeley, Jaishri O ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antineoplastic agent; Blood brain barrier; Brain tumor; Microdialysis; Tissue concentration

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CILENGITIDE; CISPLATIN; DAUNORUBICIN; ERLOTINIB; ESTRAMUSTINE; ETOPOSIDE; GEFITINIB; IDARUBICIN; IMATINIB; LAPATINIB; METHOTREXATE; MITOXANTRONE; PACLITAXEL; RANIMUSTINE; TAUROMUSTINE; TEMOZOLOMIDE; TEMSIROLIMUS; TENIPOSIDE;

AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BRAIN TUMOR; CANCER GRADING; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MIXED TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SYSTEMATIC REVIEW; TUMOR LOCALIZATION;

ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; DATABASES, FACTUAL; HUMANS; TISSUE DISTRIBUTION;

EID: 80052622812     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0564-y     Document Type: Review

References (52)

1. S Motl Y Zhuang CM Waters CF Stewart 2006 Pharmacokinetic considerations in the treatment of CNS tumours Clin Pharmacokinet 45 871 16928151 10.2165/00003088-200645090-00002 1:CAS:528:DC%2BD28XhtVGisrrI (Pubitemid 44313694)
2. R Cecchelli V Berezowski S Lundquist, et al. 2007 Modelling of the blood-brain barrier in drug discovery, development Nat Rev Drug Discov 6 650 17667956 10.1038/nrd2368 1:CAS:528:DC%2BD2sXotl2qtLc%3D (Pubitemid 47202487)
3. N Abbott 2004 Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro, in silico models Drug Discov Today Technol 1 407 10.1016/j.ddtec.2004.11.014 1:CAS:528:DC%2BD2MXhtlSqs7s%3D (Pubitemid 40186344)
4. LL Muldoon C Soussain K Jahnke, et al. 2007 Chemotherapy delivery issues in central nervous system malignancy: a reality check J Clin Oncol 25 2295 17538176 10.1200/JCO.2006.09.9861 1:CAS:528:DC%2BD2sXnsVShu7o%3D (Pubitemid 46954658)
5. J Collins R Dedrick 1983 Distributed model for drug deliver to CSF and brain tissue Am J Physiol Regul Integr Comp Physiol 245 R303 1:CAS:528:DyaL3sXlsFWksrY%3D
6. E de Lange M Danhof 2002 Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood, brain Clin Pharmacokinet 41 691 12162757 10.2165/00003088-200241100-00001
7. W Pardridge 2005 The blood-brain barrier: bottleneck in brain drug development NeuroRX J Am Soc Exp NeuroTher 2 3
8. DS Miller B Bauer AMS Hartz 2008 Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy Pharmacol Rev 60 196 18560012 10.1124/pr.107.07109 1:CAS:528:DC%2BD1MXitlWlsrs%3D (Pubitemid 351962009)
9. A Nies 2007 The role of membrane transporters in drug delivery to brain tumors Cancer Lett 254 11 17275180 10.1016/j.canlet.2006.12.023 1:CAS:528:DC%2BD2sXnvFyls7w%3D (Pubitemid 47058801)
10. S Dallas DS Miller R Bendayan 2006 Multidrug resistance-associated proteins: expression, function in the central nervous system Pharmacol Rev 58 140 16714484 10.1124/pr.58.2.3 1:CAS:528:DC%2BD28XlvVelsL0%3D
11. U Norinder M Haeberlein 2002 Computational approaches to the prediction of the blood-brain distribution Adv Drug Deliv Rev 54 291 11922949 10.1016/S0169-409X(02)00005-4 1:CAS:528:DC%2BD38Xitlartbg%3D (Pubitemid 34260955)
12. D Winkler F Burden 2004 Modelling blood-brain barrier partitioning using Bayesian neural nets J Mol Graph Model 22 499 15182809 10.1016/j.jmgm.2004.03. 010 1:CAS:528:DC%2BD2cXkslWrsb8%3D (Pubitemid 38746575)
13. Basak S, Gute B, Drewes L (1996) Predicting blood-brain transport of drugs: a computational approach. Pharm Res 13
14. DE Clark 2003 In silico prediction of blood-brain barrier permeation Drug Discov Today 8 927 14554156 10.1016/S1359-6446(03)02827-7 1:CAS:528: DC%2BD3sXnvFSiu70%3D (Pubitemid 37230012)
15. Sarin H (2009) Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. J Transl Med 7
16. Groothuis D, Vick N (1982) Brain tumors and the blood-brain barrier. Trends Neurosci 5
17. Essig M, Weber M, Von Tengg-Kobligk H, et al (2006) Contrast-enhanced magnetic resonance imaging of central nervous system tumors: agents, mechanisms, and applications. Top Magn Reson Imaging 17
18. JO Blakeley J Olson SA Grossman, et al. 2009 Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study J Neurooncol 91 51 18787762 10.1007/s11060-008-9678-2 1:CAS:528:DC%2BD1MXjvFyluw%3D%3D
19. J Ma S Pulfer S Li, et al. 2001 Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470 Cancer Res 61 5491 11454697 1:CAS:528:DC%2BD3MXlsVChsLk%3D
20. A Claes P Wesseling J Jeuken, et al. 2008 Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization Mol Cancer Ther 7 71 18187807 10.1158/1535-7163.MCT-07-0552 1:CAS:528: DC%2BD1cXmsVynsg%3D%3D
21. U Bickel 2005 How to measure drug transport across the blood-brain-barrier NeuroRX J Am Soc Exp NeuroTher 2 15
22. H Sarin A Kanevsky H Wu, et al. 2008 Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells J Transl Med 6 80 19094226 10.1186/1479-5876-6-80
23. M Alavijeh A Palmer 2009 Measurement of the pharmacokinetics, pharmacodynamics of neuroactive compounds Neurobiol Dis 37 38 19818851 10.1016/j.nbd.2009.09.025
24. Q Zhou J Gallo 2005 In vivo microdialysis for PK, PD studies of anticancer drugs AAPS J 7 E659 16353942 10.1208/aapsj070366 1:CAS:528: DC%2BD2MXhtlSrtbfN (Pubitemid 41631728)
25. J Blakeley 2008 Drug delivery to brain tumors Curr Neurol Neurosci Rep 8 235 18541119 10.1007/s11910-008-0036-8 1:CAS:528:DC%2BD1cXhtVeisLbJ
26. J Portnow B Badie M Chen, et al. 2009 The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation Clin Cancer Res 15 7092 19861433 10.1158/1078-0432.CCR-09-1349 1:CAS:528:DC%2BD1MXhtl2ktLfE
27. C Shinohara K Matsumoto M Kuriyama, et al. 1994 Clinical pharmacokinetics of carboplatin, MCNU. Gan to kagaku ryoho Cancer Chemother 21 1163 1:STN:280:DyaK2czgsVantg%3D%3D
28. IR Whittle G Malcolm DI Jodrell M Reid 1999 Platinum distribution in malignant glioma following intraoperative intravenous infusion of carboplatin Br J Neurosurg 13 132 10616580 10.1080/02688699943871 1:STN:280: DC%2BD3c%2Fotl2msQ%3D%3D (Pubitemid 29240415)
29. M Gilbert 2007 Tumor tissue delivery of celingitide after intravenous administration to patients with recurrent glioblastoma (GBM): preliminary data from NABTC protocol 03-02 Neuro-oncol 9 525
30. H Nakagawa T Fujita S Izumoto, et al. 1993 Cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer. I. Distribution within the central nervous system after intravenous, intracarotid infusion J Neurooncol 16 61 8410144 10.1007/BF01324836 1:STN:280:DyaK2c%2FhsFansA%3D%3D
31. Albrecht KW, Hamer PCdW, Leenstra S, et al (2001) High concentration of Daunorubicin and Daunorubicinol in human malignant astrocytomas after systemic administration of liposomal Daunorubicin. Journal of Neuro-Oncology 53
32. M Zucchetti A Boiardi A Silvani, et al. 1999 Distribution of daunorubicin, daunorubicinol in human glioma tumors after administration of liposomal daunorubicin Cancer Chemother Pharmacol 44 173 10412954 10.1007/s002800050964 1:CAS:528:DyaK1MXktF2ktr4%3D (Pubitemid 29297066)
33. JJ Raizer L Abrey AB Lassman, et al. 2010 A phase II trial of erlotinib in patients with recurrent malignant gliomas, nonprogressive glioblastoma multiforme postradiation therapy Neuro Oncol 12 95 20150372 1:CAS:528: DC%2BC3cXjvFCnt7Y%3D
34. AT Bergenheim PO Gunnarsson K Edman, et al. 1993 Uptake, retention of estramustine, the presence of estratmustine binding protein in malignant brain tumours in humans Br J Cancer 67 358 8431366 10.1038/bjc.1993.65 1:CAS:528:DyaK3sXhvVaktrs%3D
35. M Zucchetti C Rossi R Knerich, et al. 1991 Concentrations of VP16, VM26 in human brain tumors Ann Oncol 2 63 2009235 1:STN:280:DyaK3M7ot1KmtA%3D%3D
36. K Kiya T Uozumi H Ogasawara, et al. 1992 Penetration of etoposide into human malignant brain tumors after intravenous, oral administration Cancer Chemother Pharmacol 29 339 1312906 10.1007/BF00686001 1:STN:280: DyaK383gtVGmtw%3D%3D
37. DJ Stewart MT Richard H Hugenholtz, et al. 1984 Penetration of VP-16 (etoposide) into human intracerebral, extracerebral tumors J Neurooncol 2 133 6481426 1:STN:280:DyaL2M%2FgvVymtg%3D%3D
38. S Hofer K Frei 2007 Gefitinib concentrations in human glioblastoma tissue J Neurooncol 82 175 17008949 10.1007/s11060-006-9257-3 (Pubitemid 46431861)
39. W Boogerd IS Tjahja MMvd Sandt JH Beijnen 1999 Penetration of idarubicin into malignant brain tumor tissue J Neurooncol 44 65 10582671 10.1023/A:1006335517191 1:STN:280:DC%2BD3c%2FkslCqtA%3D%3D (Pubitemid 29515652)
40. M Holdoff J Supko GL Gallia, et al. 2009 Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme J Neurooncol 97 241 10.1007/s11060-009-0008-0
41. JG Kuhn 2008 Tumor sequestration of lapatinib Neuro-oncol 10 783
42. RM Green DJ Stewart H Hugenholtz, et al. 1988 Human central nervous system, plasma pharmacology of mitoxantrone J Neurooncol 6 75 3397768 10.1007/BF00163544 1:STN:280:DyaL1c3os1WqtA%3D%3D
43. JJ Heimans JB Vermorken JB Wolbers, et al. 1994 Paclitaxel (TAXOL) concentrations in brain tumor tissue Ann Oncol 5 951 7696168 1:STN:280:DyaK2M3htVWmsA%3D%3D
44. RL Fine J Chen C Balmaceda, et al. 2006 Randomized study of paclitaxel, tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors Clin Cancer Res 12 5770 17020983 10.1158/1078-0432.CCR- 05-2356 1:CAS:528:DC%2BD28XhtVartbvE (Pubitemid 44629608)
45. IR Whittle JS MacPherson JD Miller JF Smyth 1990 The disposition of TCNU (tauromustine) in human malignant glioma: phamacokinetic studies, clinical implications J Neurosurg 72 721 2157825 10.3171/jns.1990.72.5.0721 1:STN:280:DyaK3c3hvVaisA%3D%3D
46. JG Kuhn SM Chang PY Wen, et al. 2007 Pharmocokinetic and tumor distribution characteristics of temsirolimus Clin Cancer Res 13 7401 18094423 10.1158/1078-0432.CCR-07-0781 1:CAS:528:DC%2BD2sXhsVCktr3P
47. O van Tellingen W Boogerd WJ Nooijen JH Beijnen 1997 The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue Cancer Chemother Pharmacol 40 330 9225951 10.1007/s002800050665 (Pubitemid 27276137)
48. DJ Stewart MT Richard H Hugenholtz, et al. 1984 Penetration of teniposide (VM-26) into human intracerebral tumors J Neurooncol 2 315 6530619 1:CAS:528:DyaL2MXhsVakt7s%3D
49. R Stupp WP Mason MJ Bent, et al. 2005 Radiotherapy plus concomitant, adjuvant temozolomide for glioblastoma N Engl J Med 352 987 15758009 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D (Pubitemid 40349501)
50. E Franceschi G Cavallo S Lonardi, et al. 2007 Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) Br J Cancer 96 1047 17353924 10.1038/sj.bjc.6603669 1:CAS:528:DC%2BD2sXjsleksLw%3D (Pubitemid 46608313)
51. Mv Vulpen HB Kal MJ Taphoorn SYE Sharouni 2002 Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? Oncol Rep 9 683 12066192
52. I Martin 2004 Prediction of blood-brain barrier penetration: are we missing the point? Drug Discov Today 9 161 14960394 10.1016/S1359-6446(03)02961- 1 (Pubitemid 38199960)